Product Code: 978-1-68038-455-0
Blood Preparation Market Growth & Trends:
The global blood preparation market size is expected to reach USD 73.59 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 6.4% from 2023 to 2030. The key factors driving the market include growing prevalence of blood-related disorders, extensive usage of its components in several surgical procedures, rising number of transfusion procedures.
Rising number of injuries & accidents, increasing blood donations, and growing government initiatives to raise awareness regarding donation are expected to propel the market during the forecast period. For instance, in November 2022, the World Health Organization/ Pan American Health Organization (PAHO/WHO) with funding support from the United States of America conducted an awareness program by donating promotional items for voluntary donation to save lives in Belize . Moreover, the increasing usage of plasma as life-saving therapeutics for numerous chronic and acute life-threatening diseases such as Hemophilia and Hereditary Angioedema in the biopharmaceutical and pharmaceutical industries is likely to boost the blood preparation market.
The operating players in the market are undertaking numerous strategies such as collaborations, mergers & acquisitions, and product launches. Furthermore, the companies are also focusing on extending their investments on expansion of manufacturing facilities with an aim to meet the demand. For instance, in May 2023, PlasmaGen Biosciences announced an opening of its new facility to boost the production of blood plasma products in India . The facility aims to significantly enhance the supply-demand scenario for products at reasonable prices.
However, the growing incidence of allergic reactions through the transfusion including hypotensive transfusion reactions are anticipated to hamper the market in the study period. In addition, high changes of disease transmission during transfusions such as hepatitis B, HIV and viral hemorrhagic fever may impede the market.
On the other hand, innovations in collection and processing technologies such as automated collection systems, can improve the quality of products by reducing the processing time. For instance, in May 2022, Vitestro, introduced an innovative autonomous blood drawing device. The device is combination of ultrasound-guided 3D reconstruction and artificial intelligence (AI) with robotic needle insertion for secure and precise collection . Thus such initiatives are projected to create lucrative opportunities during the forecast period.
Blood Preparation Market Report Highlights:
- By product, the whole blood product segment held the largest market share in 2022 due to increasing demand for major surgeries and transfusions.
- By type,anticoagulants dominated the type segment in 2022 and are expected to register a lucrative CAGR from 2023 to 2030. This growth is attributed to the introduction of new products with higher efficacy and the potential commercialization of new products currently in the pipeline.
- By region, North America led the overall market in terms of revenue in 2022 owing to the high incidence of CVDs, leukemia, and hematological and neurological diseases in the region.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Market Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Product & Application Snapshot
- 2.3. Anti-thrombotic & Anticoagulants Type Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
- 4.1. Blood Preparation Market: Product Movement Analysis
- 4.2. Whole Blood
- 4.2.1. Whole Blood Market, 2018 - 2030 (USD Million)
- 4.2.2. Red Cells
- 4.2.2.1. Red Cells Market, 2018 - 2030 (USD Million)
- 4.2.3. Granulocytes
- 4.2.3.1. Granulocytes Market, 2018 - 2030 (USD Million)
- 4.2.4. Plasma
- 4.2.4.1. Plasma Market, 2018 - 2030 (USD Million)
- 4.2.5. Platelets
- 4.2.5.1. Platelets Market, 2018 - 2030 (USD Million)
- 4.3. Blood Components
- 4.3.1. Whole Blood Components
- 4.3.1.1. Whole Blood Components Market, 2018 - 2030 (USD Million)
- 4.3.2. Packed Red Cells
- 4.3.2.1. Packed Red Cells Market, 2018 - 2030 (USD Million)
- 4.3.3. Leukocyte Reduced Red Blood Cells
- 4.3.3.1. Leukocyte Reduced Red Blood Cells Market, 2018 - 2030 (USD Million)
- 4.3.4. Frozen Plasma
- 4.3.4.1. Frozen Plasma Market, 2018 - 2030 (USD Million)
- 4.3.5. Platelet Concentrate
- 4.3.5.1. Whole Blood Components Market, 2018 - 2030 (USD Million)
- 4.3.6. Cryoprecipitate
- 4.3.6.1. Cryoprecipitate Market, 2018 - 2030 (USD Million)
- 4.4. Blood Derivatives
- 4.4.1. Blood Derivatives Market, 2018 - 2030 (USD Million)
Chapter 5. Anti-Thrombotic and Anticoagulants Type Business Analysis
- 5.1. Blood Preparation Market: Anti-Thrombotic and Anticoagulants Type Movement Analysis
- 5.2. Platelet Aggregation Inhibitors
- 5.2.1. Platelets Aggregation Inhibitors Market, 2018 - 2030 (USD Million)
- 5.2.2. Glycoprotein Inhibitors
- 5.2.2.1. Glycoprotein Inhibitors Market, 2018 - 2030 (USD Million)
- 5.2.3. COX Inhibitors
- 5.2.3.1. COX Inhibitors Market, 2018 - 2030 (USD Million)
- 5.2.4. ADP Antagonist
- 5.2.4.1. ADP Antagonist Market, 2018 - 2030 (USD Million)
- 5.2.5. Others
- 5.2.5.1. Others Market, 2018 - 2030 (USD Million)
- 5.3. Fibrinolytics
- 5.3.1. Fibrinolytics Market, 2018 - 2030 (USD Million)
- 5.3.2. Tissue Plasminogen Activator
- 5.3.2.1. Others Market, 2018 - 2030 (USD Million)
- 5.3.3. Streptokinase
- 5.3.3.1. Streptokinase Market, 2018 - 2030 (USD Million)
- 5.3.4. Urokinase
- 5.3.4.1. Urokinase Market, 2018 - 2030 (USD Million)
- 5.4. Anticoagulants
- 5.4.1. Anticoagulants Market, 2018 - 2030 (USD Million)
- 5.4.2. Heparins
- 5.4.2.1. Heparins Market, 2018 - 2030 (USD Million)
- 5.4.2.2. Unfractionated heparin
- 5.4.2.2.1. Unfractionated heparin Market, 2018 - 2030 (USD Million)
- 5.4.2.3. Low Molecular Weight heparin
- 5.4.2.3.1. Low Molecular Weight Heparin Market, 2018 - 2030 (USD Million)
- 5.4.2.4. Ultra-Low Molecular Weight Heparin
- 5.4.2.4.1. Ultra-Low Molecular Weight Heparin Market, 2018 - 2030 (USD Million)
- 5.4.3. Vitamin K Antagonist
- 5.4.3.1. Vitamin K Antagonist Market, 2018 - 2030 (USD Million)
- 5.4.4. Direct Thrombin Inhibitors
- 5.4.4.1. Direct Thrombin Inhibitors Market, 2018 - 2030 (USD Million)
- 5.4.5. Direct factor Xa inhibitors
- 5.4.5.1. Direct factor Xa Inhibitors Market, 2018 - 2030 (USD Million)
Chapter 6. Application Business Analysis
- 6.1. Thrombocytosis
- 6.1.1. Thrombocytosis Market, 2018 - 2030 (USD Million)
- 6.2. Pulmonary Embolism
- 6.2.1. Pulmonary Embolism Market, 2018 - 2030 (USD Million)
- 6.3. Renal Impairment
- 6.3.1. Renal Impairment Market, 2018 - 2030 (USD Million)
- 6.4. Angina Blood Vessel Complication
- 6.4.1. Angina Blood Vessel Complication Market, 2018 - 2030 (USD Million)
- 6.5. Others
- 6.5.1. Other Application Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Blood Preparation Market Share By Region, 2022 & 2030
- 7.2. North America
- 7.2.1. SWOT Analysis
- 7.2.2. North America Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.2.3. U.S.
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. Regulatory Framework
- 7.2.3.5. U.S. Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.2.4. Canada
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Competitive Scenario
- 7.2.4.4. Regulatory Framework
- 7.2.4.5. Canada Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. SWOT Analysis
- 7.3.2. Europe Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. UK Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.4. Germany
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Germany Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.5. France
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. Regulatory Framework
- 7.3.5.5. France Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.6. Italy
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Regulatory Framework
- 7.3.6.5. Italy Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.7. Spain
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Regulatory Framework
- 7.3.7.5. Spain Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.8. Denmark
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Regulatory Framework
- 7.3.8.5. Denmark Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.9. Sweden
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Regulatory Framework
- 7.3.9.5. Sweden Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.3.10. Norway
- 7.3.10.1. Key Country Dynamics
- 7.3.10.2. Target Disease Prevalence
- 7.3.10.3. Competitive Scenario
- 7.3.10.4. Regulatory Framework
- 7.3.10.5. Norway Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. SWOT Analysis
- 7.4.2. Asia Pacific Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Japan Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.4. China
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. China Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.5. India
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. India Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Australia Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Thailand Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.4.8. South Korea
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Target Disease Prevalence
- 7.4.8.3. Competitive Scenario
- 7.4.8.4. Regulatory Framework
- 7.4.8.5. South Korea Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. SWOT Analysis
- 7.5.2. Latin America Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.5.3. Brazil
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. Brazil Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Regulatory Framework
- 7.5.4.5. Mexico Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.5.5. Argentina
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Regulatory Framework
- 7.5.5.5. Argentina Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.6. MEA
- 7.6.1. SWOT Analysis
- 7.6.2. MEA Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.6.3. South Africa
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. South Africa Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.6.4. Saudi Arabia
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Regulatory Framework
- 7.6.4.5. Saudi Arabia Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.6.5. UAE
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Regulatory Framework
- 7.6.5.5. UAE Blood Preparation Market, 2018 - 2030 (USD Million)
- 7.6.6. Kuwait
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Competitive Scenario
- 7.6.6.4. Regulatory Framework
- 7.6.6.5. Kuwait Blood Preparation Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2022
- 8.4. Company Profiles/Listing
- 8.4.1. Strategic Framework
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Pfizer, Inc
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Bristol-Myers Squibb Company
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Leo Pharma A/S
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Sanofi
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. Xiamen Hisunny Chemical Co., LTD
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. AstraZeneca plc
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Baxter International Inc
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives